The Chinese Antibody Society (CAS) Annual Conference 2025 was held in Boston, MA on May 10. The meeting was titled “New Frontiers of Bispecific Antibodies, Antibody-Drug Conjugates and Beyond” and featured the latest advancements in therapeutic antibodies, in addition to innovative approaches in their discovery, development, and manufacturing. Several prominent speakers in the biopharmaceutical field gave talks throughout the day.
Antibody biology can be mined for novel functionalities and therapeutic development.
Discovery platforms are integrating antibodies, nanobodies, biparatopics, and AI for more efficient pipeline generation.
Transferrin receptor-targeting bispecific chimeras enable degradation of membrane proteins.
Therapeutic antibodies are being developed for difficult multi-pass transmembrane protein targets.
Bispecific myeloid engagers (BiME) show promise in treating solid tumors.
Multispecific antibodies are being engineered to overcome tumor resistance mechanisms.
Trends in ADC development emphasize strategic CMC planning and case studies from GV20.
A cMET-targeting ADC demonstrates enhanced payload delivery to tumor cells.
Panelists discuss the challenges and future potential of next-generation ADCs for cancer and other diseases.
Next-generation MHC and transmembrane protein platforms are advancing tumor immunotherapy discovery.
Thank you to everyone who joined us with CAS! We had a fantastic time connecting with you and sharing how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
